Key clinical point: Oral dextromethorphan/bupropion shows promise of meeting the major unmet need for better antidepressants.
Major finding: Between-group differences in reduced depressive symptoms between AXS-05 and active comparator were documented within the first week.
Study details: This randomized, double-blind, phase 2 study included 80 patients with major depressive disorder assigned to 6 weeks of dextromethorphan/bupropion or bupropion-only as an active control.
Disclosures: The study presenter is a corporate officer at Axsome Therapeutics, the study sponsor.
O’Gorman C et al. ECNP 2019, Abstract P601.